AU5412996A - Truncated igf-i - Google Patents

Truncated igf-i

Info

Publication number
AU5412996A
AU5412996A AU54129/96A AU5412996A AU5412996A AU 5412996 A AU5412996 A AU 5412996A AU 54129/96 A AU54129/96 A AU 54129/96A AU 5412996 A AU5412996 A AU 5412996A AU 5412996 A AU5412996 A AU 5412996A
Authority
AU
Australia
Prior art keywords
truncated igf
igf
truncated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU54129/96A
Inventor
Rolf Eriksson
Stig Johansson
Harriet Ronnholm
Anna Skottner
Karin Sonesson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Health AB
Original Assignee
Pharmacia AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia AB filed Critical Pharmacia AB
Publication of AU5412996A publication Critical patent/AU5412996A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU54129/96A 1995-04-21 1996-04-19 Truncated igf-i Abandoned AU5412996A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9501472 1995-04-21
SE9501472A SE9501472D0 (en) 1995-04-21 1995-04-21 Truncated IGF-I
PCT/SE1996/000520 WO1996033216A1 (en) 1995-04-21 1996-04-19 Truncated igf-i

Publications (1)

Publication Number Publication Date
AU5412996A true AU5412996A (en) 1996-11-07

Family

ID=20398031

Family Applications (1)

Application Number Title Priority Date Filing Date
AU54129/96A Abandoned AU5412996A (en) 1995-04-21 1996-04-19 Truncated igf-i

Country Status (4)

Country Link
AU (1) AU5412996A (en)
IL (1) IL117907A0 (en)
SE (1) SE9501472D0 (en)
WO (1) WO1996033216A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6048964A (en) * 1995-12-12 2000-04-11 Stryker Corporation Compositions and therapeutic methods using morphogenic proteins and stimulatory factors
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
SE9802938D0 (en) 1998-09-01 1998-09-01 Astra Ab Improved stability for injection solutions
AU762351B2 (en) 1999-01-06 2003-06-26 Genentech Inc. Insulin-like growth factor (IGF) I mutant variants
WO2000040612A1 (en) 1999-01-06 2000-07-13 Genentech, Inc. Insulin-like growth factor (igf) i mutant variants
NZ515964A (en) * 1999-06-21 2004-03-26 Murdoch Childrens Res Inst A method for the prophylaxis and/or treatment of medical disorders
WO2001087323A2 (en) 2000-05-16 2001-11-22 Genentech, Inc. Method for treating cartilage disorders
BR0207422A (en) 2001-02-09 2005-04-19 Genentech Inc Igf-1 crystal, composition, method of treating mammals suffering from agonist dysfunction, crystallization of igf-1, crystalline igf-1, identification methods of indirect igf-1 agonists, co-crystalline complex , igf-1 three-dimensional structure determination method, machine readable data storage medium, igf-1 crystal, igf-1 three-dimensional structure use method, igf-1 agonist or antagonist identification method, compound design method, peptidomimetic identification method, method for determining at least a three-dimensional structure part of a molecular complex, method for assessing the ability of a chemical entity to associate with igf-1, chemical entity, derivative of heavy atom, method of experimental or computational evaluation of a chemical entity and use of a composition
WO2002072780A2 (en) 2001-03-14 2002-09-19 Genentech, Inc. Igf antagonist peptides
PL2274978T3 (en) 2003-09-12 2015-11-30 Ipsen Biopharmaceuticals Inc Methods for treatment of insulin-like growth factor-I(IGF-I) deficiency
WO2021005604A1 (en) 2019-07-11 2021-01-14 Opko Biologics Ltd. Long-acting igf-1 or igf-1 variants and methods of producing same
GB201913196D0 (en) 2019-09-12 2019-10-30 Univ Newcastle Culture method

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
GB9217696D0 (en) * 1992-08-20 1992-09-30 Agricultural & Food Res Use of specific binding molecules
SE9402332D0 (en) * 1994-07-01 1994-07-01 Pharmacia Ab IGF-1

Also Published As

Publication number Publication date
IL117907A0 (en) 1996-08-04
SE9501472D0 (en) 1995-04-21
WO1996033216A1 (en) 1996-10-24

Similar Documents

Publication Publication Date Title
AU5235796A (en) o-hydroxyphenyl-s-triazines
AU4780896A (en) Core-board
AU6000496A (en) Phenylpyridazinones
AU1030997A (en) Taphane
AU4996696A (en) 2-benzyl-3-arylbenzothiophenes
AU5147496A (en) Fucopeptides
AU5412996A (en) Truncated igf-i
AU6235496A (en) Azothiophenes
AU5593896A (en) Benzisothiazolyl-substituted aminomethylchromans
AU5500196A (en) Anti-transpirants
AU4382896A (en) Acetylimidazobenzodiazepines
AU5108596A (en) Morphine-3-esters
AU7038196A (en) 1-azinyl-tetrazolinones
AU6215196A (en) Piperidinylmethyloxazolidinones
AU5917896A (en) Poly-beta-1-4-N-acetylglucosamine
AU5013796A (en) Wireclamp
AU5107096A (en) Haemodialyser
AU6840796A (en) Sack-holder
AU7694696A (en) Cyclopeptolides
AU4569496A (en) Tetralinyl- and indanyl-ethylamides
AU6841596A (en) Solution containing igf-i
AU7565396A (en) Fluorobutenoyloxyacetamides
AU6658396A (en) Polyhydroxyalkylamidobetaine
AU4831396A (en) Pyrazolotetracyclines
AU5878096A (en) Fasciotome